Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes Management
Diabetes Medication and Drugs
Sulfonylureas: Just Stop
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="Alexandra100" data-source="post: 1858282" data-attributes="member: 429870"><p>From Medscape Monday, August 13, 2018:</p><p></p><p><span style="font-size: 22px"><strong>Sulfonylureas: Just Stop</strong></span></p><p>Charles P. Vega, MD</p><p></p><p><a href="https://www.medscape.com/viewarticle/899506" target="_blank">according to a new study of 77,000 patients in the UK Clinical Practice Research Datalink.</a></p><p></p><p>Patients taking sulfonylureas as second-line therapy—replacing rather than adding on to metformin—had increased risks for myocardial infarction, all-cause mortality, and severe hypoglycemia compared with those on metformin monotherapy. This was true even when metformin-only patients had suboptimal glycemic control.</p><p></p><p>This class of drugs is also associated with weight gain, which may contribute to arrhythmias and cardiac ischemia.</p><p></p><p>Current guidelines downplay the use of sulfonylureas, although they remain the most common second-line agents for type 2 diabetes despite their consistent association with higher cardiovascular risk and the availability of newer classes of medications.</p><p></p><p>An editorial[<a href="https://www.medscape.com/viewarticle/899506" target="_blank"><img src="https://img.medscapestatic.com/news/2014/ts_140618_heart_pill_800x600.jpg?interpolation=lanczos-none&resize=75:55" alt="" class="fr-fic fr-dii fr-draggable " style="" />Switching From Metformin to Sulfonylurea Raises CV Risks </a></p><p></p><p>An editorial[1] reminded us that continuing metformin alone and accepting higher A1c targets is preferable to switching to sulfonylureas for both macrovascular outcomes and hypoglycemia.</p><p></p><p><strong>Examples of sulfonylureas:</strong></p><ul> <li data-xf-list-type="ul">Glimepiride (Amaryl)</li> <li data-xf-list-type="ul">Glyburide (DiaBeta; Micronase)</li> <li data-xf-list-type="ul">Glipizide (Glucotrol)</li> </ul></blockquote><p></p>
[QUOTE="Alexandra100, post: 1858282, member: 429870"] From Medscape Monday, August 13, 2018: [SIZE=6][B]Sulfonylureas: Just Stop[/B][/SIZE] Charles P. Vega, MD [URL='https://www.medscape.com/viewarticle/899506']according to a new study of 77,000 patients in the UK Clinical Practice Research Datalink.[/URL] Patients taking sulfonylureas as second-line therapy—replacing rather than adding on to metformin—had increased risks for myocardial infarction, all-cause mortality, and severe hypoglycemia compared with those on metformin monotherapy. This was true even when metformin-only patients had suboptimal glycemic control. This class of drugs is also associated with weight gain, which may contribute to arrhythmias and cardiac ischemia. Current guidelines downplay the use of sulfonylureas, although they remain the most common second-line agents for type 2 diabetes despite their consistent association with higher cardiovascular risk and the availability of newer classes of medications. An editorial[[URL='https://www.medscape.com/viewarticle/899506'][IMG]https://img.medscapestatic.com/news/2014/ts_140618_heart_pill_800x600.jpg?interpolation=lanczos-none&resize=75:55[/IMG]Switching From Metformin to Sulfonylurea Raises CV Risks [/URL] An editorial[1] reminded us that continuing metformin alone and accepting higher A1c targets is preferable to switching to sulfonylureas for both macrovascular outcomes and hypoglycemia. [B]Examples of sulfonylureas:[/B] [LIST] [*]Glimepiride (Amaryl) [*]Glyburide (DiaBeta; Micronase) [*]Glipizide (Glucotrol) [/LIST] [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes Management
Diabetes Medication and Drugs
Sulfonylureas: Just Stop
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…